Last reviewed · How we verify

NCT07361445

Agilis RF TSP Early Feasibility Study

Recruiting now NA Last updated 11 March 2026
What this trial tests

NA trial testing Transseptal procedure with Agilis RF TSP System. in Cardiac Arrythmias in 20 participants. Currently enrolling.

Timeline
16 February 2026
Primary endpoint
1 June 2026
3 August 2026

Quick facts

Lead sponsorAbbott Medical Devices
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date16 February 2026
Primary completion1 June 2026
Estimated completion3 August 2026
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Devices — full company profile →

Who can join

18 and older, any sex, with Cardiac Arrythmias or Left Atrial Appendage Closure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, acute, first-in-human, early feasibility study intended to assess the initial safety and performance of the Agilis™ Radiofrequency (RF) Transseptal (TSP) System in crossing the atrial septum for left atrial and left ventricular access during cardiac electrophysiology (EP) and interventional cardiology (IC) procedures. This study will be conducted in an acute setting. Subjects will be followed through hospital discharge, and no follow-up visits will be required for this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiac Arrythmias

Currently open trials in the same condition.

Other Abbott Medical Devices trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07361445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing